StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.45+0.30 (+13.95%)

Close on Nov 17, 2026Market cap $106.08MP/E –Yield –

NRX Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

NRX Pharmaceuticals's total assets was $34.16M at Jun 30, 2026. For fiscal 2025 it was $12.96M, up 254.9% from the year before. The highest annual figure on record is $70.80M in fiscal 2018.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.96M+254.9%
FY2024Dec 31, 2024$3.65M-50.1%
FY2023Dec 31, 2023$7.32M-71.7%
FY2022Dec 31, 2022$25.82M-21.1%
FY2021Dec 31, 2021$32.73M+1012.8%
FY2020Dec 31, 2020$2.94M-90.8%
FY2019Dec 31, 2019$32.07M-54.7%
FY2018Dec 31, 2018$70.80M+1.8%
FY2017Dec 31, 2017$69.57M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$34.16M+606.1%
Q1 FY2026Mar 31, 2026$11.90M+56.8%
Q4 FY2025Dec 31, 2025$12.96M+254.9%
Q3 FY2025Sep 30, 2025$15.00M+236.1%
Q2 FY2025Jun 30, 2025$4.84M-8.1%
Q1 FY2025Mar 31, 2025$7.59M+100.4%
Q4 FY2024Dec 31, 2024$3.65M-50.1%
Q3 FY2024Sep 30, 2024$4.46M-66.0%
Q2 FY2024Jun 30, 2024$5.26M-73.4%
Q1 FY2024Mar 31, 2024$3.79M-82.6%
Q4 FY2023Dec 31, 2023$7.32M-71.7%
Q3 FY2023Sep 30, 2023$13.11M-47.2%
Q2 FY2023Jun 30, 2023$19.81M-38.9%
Q1 FY2023Mar 31, 2023$21.78M-50.0%
Q4 FY2022Dec 31, 2022$25.82M-21.1%
Q3 FY2022Sep 30, 2022$24.82M-45.1%
Q2 FY2022Jun 30, 2022$32.43M+74.9%
Q1 FY2022Mar 31, 2022$43.60M+623.3%
Q4 FY2021Dec 31, 2021$32.73M+1012.8%
Q3 FY2021Sep 30, 2021$45.25M+650.2%
Q2 FY2021Jun 30, 2021$18.55M+195.5%
Q1 FY2021Mar 31, 2021$6.03M-3.9%
Q4 FY2020Dec 31, 2020$2.94M-90.8%
Q3 FY2020Sep 30, 2020$6.03M-85.5%
Q2 FY2020Jun 30, 2020$6.28M-87.5%
Q1 FY2020Mar 31, 2020$6.27M-91.3%
Q4 FY2019Dec 31, 2019$32.07M-54.7%
Q3 FY2019Sep 30, 2019$41.69M-40.4%
Q2 FY2019Jun 30, 2019$50.10M-28.1%
Q1 FY2019Mar 31, 2019$71.71M+3.1%
Q4 FY2018Dec 31, 2018$70.80M+1.8%
Q3 FY2018Sep 30, 2018$69.89M–
Q2 FY2018Jun 30, 2018$69.70M–
Q1 FY2018Mar 31, 2018$69.55M–
Q4 FY2017Dec 31, 2017$69.57M–

More NRX Pharmaceuticals figures

See a number that looks wrong?